- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.01. | Evelo Biosciences, Inc. - 15-12G, Securities registration termination | 1 | SEC Filings | ||
| 26.01. | Evelo Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.12.23 | NSE - Evelo Biosciences, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 3 | SEC Filings | ||
| 26.12.23 | Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technology; Athersys, Inc.; Borqs Technologies; ContraFect Corporation; CohBar, Inc.; AgileThought, Inc.; Fat Projects Acquisition; Evelo Biosciences ... | 1.366 | GlobeNewswire (Europe) | NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of SmileDirectClub, Inc. SmileDirectClub, Inc.'s securities were suspended on... ► Artikel lesen | |
| 04.12.23 | Evelo Biosciences, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 22.11.23 | Evelo Bio Shutdown Follows a Series of Microbiome Therapy Trial Failures | 5 | MedCity News | ||
| 22.11.23 | Evelo's voyage ends, as Flagship-founded biotech finds dissolution is only viable option | 6 | FierceBiotech | ||
| 21.11.23 | Evelo Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.11.23 | Evelo Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.10.23 | Evelo Biosciences, Inc.: Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis | 417 | GlobeNewswire (Europe) | - Primary endpoint was not achieved - - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 14.08.23 | Evelo Biosciences, Inc.: Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights | 660 | GlobeNewswire (Europe) | - EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023- Completed $25.5 Million Private Placement- Restructured and reduced secured debt with Horizon... ► Artikel lesen | |
| 29.06.23 | Evelo Biosciences, Inc.: Evelo Biosciences Announces Reverse Stock Split Effective | 445 | GlobeNewswire (Europe) | - EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 - CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,940 | +0,90 % | Qiagen: Leicht enttäuschend | Der Labordienstleister und Diagnostikspezialist Qiagen rechnet in einem herausfordernden Umfeld mit einer Stabilisierung seiner Geschäfte. Bei konstanten Wechselkursen soll der Konzernumsatz des zweiten... ► Artikel lesen | |
| EVOTEC | 9,760 | -1,36 % | Delivery Hero, pbb, Evotec, K+S, TAG Immobilien, Varta und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 45,110 | +4,06 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 37,400 | +3,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,000 | -6,98 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,080 | +0,31 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| NUVALENT | 70,35 | -2,95 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| CG ONCOLOGY | 36,270 | -8,18 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| JANUX THERAPEUTICS | 64,78 | +3,76 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| ANNEXON | 4,880 | +4,72 % | Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? | ||
| SANA BIOTECHNOLOGY | 10,440 | +6,75 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
| CABALETTA BIO | 12,390 | -1,67 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 26,450 | +3,40 % | Navigating 7 Analyst Ratings For Avidity Biosciences |
Das Unternehmen EVELO BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,317 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
